Nov 12, 2026  ·  1 min read

AlphaGenome 2 predicts variant effects in specific cell types

Google DeepMind released AlphaGenome 2 on November 11 through the AlphaGenome API for noncommercial research, with a private preview for commercial research. The model takes a DNA sequence of up to 1,048,576 base pairs and a biological condition, such as a cell type or state. It predicts how a change in the sequence could affect gene activity in that setting.

Google DeepMind reports that AlphaGenome 2 identified 30% of causal variants in an immune-cell benchmark, compared with 16% for the original model fine-tuned on single-cell data. Researchers can also supply gene activity measurements from their own experiment to study a cell state the model has never seen. The release is for research use, and clinical or diagnostic use has yet to be validated.

Source  ·  Google DeepMind ↗ AlphaGenome 2: Deciphering how cells read DNA to better understand disease AlphaGenome 2 is our next-generation DNA sequence model that bridges single-cell biology and human genetics, predicting how variants affect human cell types.
  1. Nov 17Helus says its psychedelic pill beat placebo in a depression trial
  2. Nov 17HHS finalizes HIPAA changes: 15-day record access and health app transfers
  3. Nov 17FBI warns attackers are using the Artex AI hacking tool against companies
  4. Nov 16OpenAI lets its AI helpers complete your purchases
  5. Nov 16Fusion launches an early funding program for defense startups

This is our sketchbook.

Two stoneware cups turned towards each other, as if in conversation

Got a good project?
Let’s work on it together.

Let’s talk →

info@ndot.io · New Jersey · Budapest · Biel